As a result, the median overall survival (OS) of metastatic HER2-positive breast cancer patients has reached 56 months.1 Despite effective new agents, metastatic breast cancer remains incurable since the tumours eventually acquire resistance to the agents. This evidence concerns the gene ERBB2 and breast cancer.